TARGET_ID,TARGET_NAME,DRUG_ID,DRUG_OR_CHEMICAL_NAME,PRODUCT_CATEGORY,MOLECULAR_MECHANISM,CELLULAR_MECHANISM,UNDER_ACTIVE_DEVELOPMENT,HIGHEST_PHASE,LEAD_COMPOUND,CONDITIONS,CAS_NO,ORIGINATOR_ORGANIZATIONS,OTHER_ORGANIZATIONS,SMILES,SEQUENCE
2003704,Calcium/calmodulin-dependent protein kinase type II subunit alpha (CaMK-IIalpha),91383,Trifluoperazine hydrochloride,Not Specified,Breast Cancer-Resistant Protein (BCRP; ABCG2) Inhibitors; Calcium/Calmodulin-Dependent Protein Kinase II (CaMK-II) Inhibitors; Dopamine D2 Antagonists; Sodium Channel Protein Type 4 Subunit alpha (Nav1.4) Channel Blockers; Sodium Channel Protein Type 9 Subunit alpha (Nav1.7) Channel Blockers,Signal Transduction Modulators,Y,Launched,Y,Depression; Anxiety; Psychosis,000117-89-5,GlaxoSmithKline plc,Sanofi SA,CN1CCN(CC1)CCCN2c3ccccc3Sc4c2cc(cc4)C(F)(F)F.Cl.Cl,
2004400,"Peptidase inhibitor 3, skin-derived (Elafin)",103159,Lodelaben,Not Specified,Elastase Inhibitors,,N,Preclinical,Y,"Emphysema, pulmonary; Arthritis",093105-81-8,Pfizer Inc.,,CCCCCCCCCCCCCCCCCC(c1ccc(c(c1)Cl)C(=O)O)O,
2000344,Aldose Reductase (Aldehyde reductase),123910,N-[5-(Heptafluoropropyl)-6-methoxy-1-naphthylthioxomethyl]-N-methylglycine,Not Specified,Aldose Reductase Inhibitors,,N,Biological Testing,Y,Diabetic complications,,Pfizer Inc.,,CN(CC(=O)O)C(=S)c1cccc2c1ccc(c2C(C(F)(F)F)(C(F)(F)F)F)OC,
2011293,Lipoxygenase (nonspecified subtype),125691,"2-[3-(1-Hydroxyhexyl)phenoxymethyl]-1,2-dihydro- quinoline",Not Specified,Lipoxygenase Inhibitors,,N,Biological Testing,Y,"Asthma, allergic",,USV Pharmaceutical Corp.,,CCCCCC(c1cccc(c1)OCC2C=Cc3ccccc3N2)O,
2006009,Calcium channels (nonspecified subtype),126954,"2-(2,5-Dimethylpyrrolyl)ethyl 5-(methoxycarbonyl)--2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyri- dine-3-carboxylate",Not Specified,Calcium Channel Blockers,,N,Biological Testing,Y,Hypertension,,UCB SA,,Cc1ccc(n1CCOC(=O)C2=C(NC(=C(C2c3cccc(c3)[N+](=O)[O-])C(=O)OC)C)C)C,
2000171,Progesterone receptor (isoform B),127073,"11beta-(4-Acetylphenyl)-17beta-hydroxy-17alpha- -[3-hydroxy-1(Z)-propenyl]estra-4,9-dien-3-one",Not Specified,Progesterone Receptor Antagonists,Signal Transduction Modulators,N,Biological Testing,Y,Contraception,,Bayer Schering Pharma AG,,CC(=O)c1ccc(cc1)[C@H]2C[C@]3(C(CC[C@]3(/C=C\CO)O)C4C2=C5CCC(=O)C=C5CC4)C,
2000171,Progesterone receptor (isoform B),129025,"17alpha-Hydroxy-6beta-methyl-11beta-[4-(dimethyl- amino)phenyl]-17beta-(2-propynyl)-estra-4(5),9(10)-dien-3-one",Not Specified,Antiglucocorticoids; Progesterone Receptor Antagonists,Signal Transduction Modulators,N,Biological Testing,Y,Cancer,,Pfizer Inc.,,CC#C[C@]1(CCC2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4[C@@H](CC23)C)c5ccc(cc5)N(C)C)C)O,
2000944,Thromboxane-A synthase (isoform 1),131562,"[1S-(1beta,2alpha,3alpha,4beta)]-7-[3-[1-Oxo-3-(pentylamino)-3-thioxopropylaminomethyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5(Z)-heptenoic acid",Not Specified,Prostanoid TP Antagonists; Thromboxane Synthase Inhibitors,Signal Transduction Modulators,N,Biological Testing,Y,Thrombosis,,Bristol-Myers Squibb Co.,,CCCCCNC(=S)CC(=O)NC[C@@H]1[C@H]2CC[C@@H]([C@@H]1C/C=C\CCCC(=O)O)O2,
2000136,beta2-Adrenoceptor,138381,Salbutamol sulfate,Not Specified,beta2-Adrenoceptor Agonists,Signal Transduction Modulators,Y,Launched,Y,Idiopathic pulmonary fibrosis; Asthma; Bronchospasm; Chronic obstructive pulmonary disease (COPD); Acute respiratory distress syndrome (ARDS); Pain,018559-94-9,3M Pharmaceuticals; GlaxoSmithKline plc,"Acerus Pharmaceuticals Corp.; Amphastar Pharmaceuticals, Inc.; AstraZeneca plc; Chiesi Farmaceutici SpA; Ivax Corp.; Merck & Co., Inc.; Mylan NV; National Heart, Lung, and Blood Institute (NHLBI); Orion Corp. (FI); Relmada Therapeutics, Inc.; Teva Pharmaceutical Industries Ltd.; Zambon Co. SpA",CC(C)(C)NCC(c1ccc(c(c1)CO)O)O.CC(C)(C)NCC(c1ccc(c(c1)CO)O)O.OS(=O)(=O)O,